Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma of All Anatomic Sites of Origin and Non-adenoid Cystic Carcinoma Malignant Tumors of the Salivary Gland

NCT03146650 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT03146650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03146650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma of All Anatomic Sites of Origin and Non-adenoid Cystic Carcinoma Malignant Tumors of the Salivary Gland
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Unknown status
Start date
May 19, 2017
Completion date
August 11, 2025
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

major salivary gland carcinoma, minor salivary gland carcinoma, recurrent salivary gland carcinoma, stage iv major salivary gland carcinoma, stage iva major salivary gland carcinoma, stage ivb major salivary gland carcinoma, stage ivc major salivary gland carcinoma